Comparative Pharmacology
Head-to-head clinical analysis: AXOTAL versus MICRAININ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXOTAL versus MICRAININ.
AXOTAL vs MICRAININ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Renal excretion of unchanged drug (60-70%) and glucuronide conjugates (10-20%); biliary excretion (5-10%); fecal elimination (<10%).
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Category C
Category C
Barbiturate Combination Analgesic
Barbiturate Combination Analgesic